Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Letter
Oncology
Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi, Masahito Shimizu
Summary: This study aimed to evaluate the efficacy and safety of BRAC combination therapy in patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma. The results showed that BRAC therapy had a good response rate but also caused significant hematological toxicity.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Mazyar Shadman
Summary: Mantle cell lymphoma remains incurable despite recent treatment advances, making individualized treatment crucial for patients. Early intervention based on high-risk features and disease progression stage is essential for improved treatment outcomes.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Hematology
Kunal C. Potnis, Mengyang Di, Iris Isu, Lohith Gowda, Stuart E. Seropian, Francine M. Foss, Howard P. Forman, Scott F. Huntington
Summary: In March 2021, CAR T-cell therapy was approved for use in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The cost-effectiveness of CAR T-cell therapy compared to standard of care therapies in FL patients is unknown.
Article
Oncology
Alan Z. Skarbnik, Krish Patel
Summary: Follicular lymphoma (FL) is a common lymphoma with a variable clinical course. The response to treatment decreases with each line of therapy, and poor survival outcomes are associated with disease progression within 24 months of initial treatment. Although rituximab-based regimens are preferred for early lines of treatment, there is no clear standard of care for third-line treatment or later.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Katsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, Masaki Iino, Jun Takizawa, Yoshinobu Maeda, Kazuhiko Yamamoto, Shinobu Tamura, Akiyo Yoshida, Hideo Yagi, Isao Yoshida, Koichi Kitazume, Taro Masunari, Ilseung Choi, Yasutaka Kakinoki, Ritsuro Suzuki, Tadashi Yoshino, Shigeo Nakamura, Yoshihiro Hatta, Takashi Yoshida, Masatoshi Kanno
Summary: The study evaluated the efficacy and safety of consolidation therapy with Y-90-IT after re-induction therapy with BR in patients with previously treated FL. Among the 22 patients who received Y-90-IT consolidation, the 2-year PFS rate was 59%, and patients whose remission lasted ≥2 years had a significantly higher PFS rate. Major adverse events were hematological toxicities, but acceptable, and the estimated 2-year overall survival after consolidation was 95%.
HEMATOLOGICAL ONCOLOGY
(2021)
Review
Oncology
Najat Bouchkouj, Megan Zimmerman, Yvette L. Kasamon, Cong Wang, Tianjiao Dai, Zhenzhen Xu, Xiaofei Wang, Marc Theoret, Tejashri Purohit-Sheth, Bindu George
Summary: This article summarizes the clinical review and regulatory considerations on the approval of axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. The study showed high objective response rate and long duration of response in patients who received the therapy. However, safety concerns were also identified, leading to the implementation of a risk evaluation and mitigation strategy.
Review
Hematology
Toby A. Eyre, Chan Y. Cheah, Michael L. Wang
Summary: This review discusses the key therapeutic approaches in the management of relapsed mantle cell lymphoma (MCL), with a focus on the use of covalent Bruton tyrosine kinase (BTK) inhibitors. The review also explores treatment options after BTK inhibitor therapy, including chimeric antigen receptor T-cell therapy and novel therapies.
Article
Hematology
Christopher J. Forlenza, Nitya Gulati, Audrey Mauguen, Michael J. Absalon, Sharon M. Castellino, Anna Franklin, Frank G. Keller, Neerav Shukla
Summary: In this study, BVB was found to be well tolerated in pediatric patients with R/R HL and compared favorably with currently accepted salvage regimens, showing promising efficacy and outcomes in this population.
Article
Hematology
Kayoko Murayama, Toru Kiguchi, Koji Izutsu, Yoshihiro Kameoka, Michihiro Hidaka, Harumi Kato, Shinya Rai, Junya Kuroda, Kenichi Ishizawa, Satoshi Ichikawa, Kiyoshi Ando, Michinori Ogura, Koji Fukushima, Yasuhito Terui
Summary: This study aimed to confirm the effectiveness and tolerability of bendamustine-rituximab combination therapy in patients with relapsed/refractory diffuse large B cell lymphoma. The results showed that the combination therapy was effective in achieving disease response and was well tolerated, with an overall response rate of 76.3% in the patients.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Franck Morschhauser, Nilanjan Ghosh, Izidore S. Lossos, M. Lia Palomba, Amitkumar Mehta, Olivier Casasnovas, Don Stevens, Sudhakar Katakam, Andrea Knapp, Tina Nielsen, Ron McCord, Gilles Salles
Summary: The triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) showed effectiveness and tolerability in patients with relapsed/refractory follicular lymphoma (FL), with a 36-month progression-free survival rate of 68.4%. Adverse events were noted in all treated patients, with two fatal events reported, both unrelated to the study drug.
BLOOD CANCER JOURNAL
(2021)
Article
Hematology
Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martin-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell
Summary: Nivolumab monotherapy showed limited activity in patients with relapsed or refractory follicular lymphoma (FL), and better understanding of the immune biology of the disease may facilitate the development of effective checkpoint-based strategies.
Article
Medicine, General & Internal
Nuri Karadurmus, Semra Paydas, Ece Esin, Zeki Gokhan Surmeli, Birol Yildiz, Ismail Erturk, Erdinc Nayir, Mutlu Dogan, Ahmet Taner Sumbul, Ibrahim Barista, Emel Gurkan, Ramazan Ocal, Burhan Ferhanoglu, Gokhan Ozgur, Yusuf Karakas, Sahin Lacin, Sukru Ozaydin, Halil Ibrahim Petekkaya, Necdet Uskent
Summary: Bendamustine showed a high objective response rate in relapsed/refractory lymphoma patients, making it an effective salvage treatment option. However, common side effects include lymphopenia, anemia, and neutropenia.
ARCHIVES OF MEDICAL SCIENCE
(2021)
Article
Oncology
Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung-Sook Lee, Cheolwon Suh, Dok Hyun Yoon, Inho Kim, Seung-Hyun Nam, Mark Hong Lee, Jong Ho Won, Jee Hyun Kong, Seong Hyun Jeong, Suk Joong Oh, Keon Woo Park, Jae Joon Han, Moo-Kon Song, Sung Hyun Yang, Im Il Na, Hyo-Rak Lee, Dong-Yeop Shin, Hye Jin Kang
Summary: This study evaluated the safety and efficacy of I-131-rituximab in patients with relapsed or refractory follicular or mantle cell lymphoma. 24 patients were enrolled, and treatment response was assessed with contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography. The results showed that I-131-rituximab had an effective and favorable safety profile, with a median progression-free survival of 5.9 months and overall survival of 37.9 months.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, Basem M. William, Javier Munoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu
Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.
Article
Biochemical Research Methods
Dmitri V. Rozanov, Nikita D. Rozanov, Kami E. Chiotti, Ashok Reddy, Phillip A. Wilmarth, Larry L. David, Seung W. Cha, Sunghee Woo, Pavel Pevzner, Vineet Bafna, Gregory G. Burrows, Juha K. Rantala, Trevor Levin, Pavana Anur, Katie Johnson-Camacho, Shaadi Tabatabaei, Daniel J. Munson, Tullia C. Bruno, Jill E. Slanskyk, John W. Kappler, Naoto Hirano, Sebastian Boegel, Bernard A. Fox, Colt Egelston, Diana L. Simons, Grecia Jimenez, Peter P. Lee, Joe W. Gray, Paul T. Spellman
JOURNAL OF PROTEOMICS
(2018)
Article
Mathematical & Computational Biology
Esra Kurum, Daniel R. Jeske, Carolyn E. Behrendt, Peter Lee
STATISTICS IN MEDICINE
(2018)
Review
Immunology
Antigoni Poultsidi, Yiannis Dimopoulos, Ting-Fang He, Triantafyllos Chavakis, Emmanouil Saloustros, Peter P. Lee, Constantinos Petrovas
FRONTIERS IN IMMUNOLOGY
(2018)
Article
Immunology
Lei Wang, Diana L. Simons, Xuyang Lug, Travis Y. Tu, Shawn Solomon, Roger Wang, Anthony Rosario, Christian Avalos, Daniel Schmolze, John Yim, James Waismans, Peter P. Lee
Article
Medicine, General & Internal
Arjun Kalvala, Pierre Wallet, Lu Yang, Chongkai Wang, Haiqing Li, Arin Nam, Anusha Nathan, Isa Mambetsariev, Valeriy Poroyko, Hanlin Gao, Peiguo Chu, Martin Sattler, Andrea Bild, Edwin R. Manuel, Peter P. Lee, Mohit Kumar Jolly, Prakash Kulkarni, Ravi Salgia
JOURNAL OF CLINICAL MEDICINE
(2019)
Article
Physics, Applied
David R. Mittelstein, Jian Ye, Erika F. Schibber, Ankita Roychoudhury, Leyre Troyas Martinez, M. Houman Fekrazad, Michael Ortiz, Peter P. Lee, Mikhail G. Shapiro, Morteza Gharib
APPLIED PHYSICS LETTERS
(2020)
Article
Medicine, Research & Experimental
Dayson Moreira, Sagus Sampath, Haejung Won, Seok Voon White, Yu-Lin Su, Marice Alcantara, Chongkai Wang, Peter Lee, Ellie Maghami, Erminia Massarelli, Marcin Kortylewski
Summary: The study suggests that targeted inhibition of STAT3 in tumor-associated myeloid cells enhances the efficacy of radiotherapy against HNSCC by promoting the recruitment of CD8(+) T cells and suppressing tumor growth.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Oncology
Dobrin Draganov, Zhen Han, Aamir Rana, Nitasha Bennett, Darrell J. Irvine, Peter P. Lee
Summary: Ivermectin induces immunogenic cancer cell death and promotes T cell infiltration in breast tumors, while targeting immunosuppressive populations. Combination therapy with anti-PD1 antibody shows synergy in limiting tumor growth and triggering anti-tumor immune responses.
Article
Biology
Adarsh Kumbhari, Danya Rose, Peter P. Lee, Peter S. Kim
Summary: T cells play a crucial role in cancer immunity through their avidity, with high-avidity T cells being essential for durable anti-cancer responses. Optimizing vaccine schedules can help preferentially select high-avidity T cells, which may lead to more effective cancer immunotherapy strategies.
MATHEMATICAL BIOSCIENCES
(2021)
Article
Oncology
Jian Ye, Weihua Guo, Chongkai Wang, Colt A. Egelston, Massimo D'Apuzzo, Geereesh Shankar, Marwan G. Fakih, Peter P. Lee
Summary: Our study reveals significant variations in functional status and spatial distribution of immune cells across different metastatic sites in MSS colorectal cancer. These findings suggest that metastatic site-dependent immune contexture may underlie discordant responses to ICI therapy in patients with MSS colorectal cancer.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Thanh H. Dellinger, Ernest S. Han, Mustafa Raoof, Byrne Lee, Xiwei Wu, Hyejin Cho, Ting-Fang He, Peter Lee, Marianne Razavi, Winnie S. Liang, Daniel Schmolze, Saul J. Priceman, Stephen Lee, Wei-Chien Lin, Jeff F. Lin, Mehdi Kebria, Amy Hakim, Nora Ruel, Daphne B. Stewart, Edward W. Wang, Benjamin Paz, Mark T. Wakabayashi, Mihaela C. Cristea, Lorna Rodriguez-Rodriguez
Summary: This study evaluated the clinical and safety outcomes of HIPEC treatment in ovarian cancer patients, identifying distinct transcriptomic signatures correlating with treatment response. Molecular changes induced by HIPEC in good responders included upregulation of immune pathways and downregulation of DNA repair pathways. These findings confirm preclinical model results for the first time in a human cohort.
JCO PRECISION ONCOLOGY
(2022)
Review
Oncology
Aleksandra Karolak, Sergio Branciamore, Jeannine S. McCune, Peter P. Lee, Andrei S. Rodin, Russell C. Rockne
Summary: The success of immune-modulating therapies for cancer has led to research on information flow within the immune system and the application of information theory concepts in clinical settings. Information theory allows for the quantification of information storage, transmission, encoding, and flow within and between cellular components of the immune system, aiding in understanding immune signaling function and dysfunction in cancer at a quantitative level.
Article
Medicine, General & Internal
Eric E. Jung, F. Scott Heinemann, Colt A. Egelston, Jennifer Wang, Raphael E. Pollock, Peter P. Lee, William W. Tseng
Article
Oncology
Kim R. M. Blenman, Ting-Fang He, Paul H. Frankel, Nora H. Ruel, Erich J. Schwartz, David N. Krag, Lee K. Tan, John H. Yim, Joanne E. Mortimer, Yuan Yuan, Peter P. Lee
Article
Oncology
Chongkai Wang, Jun Gong, Travis Y. Tu, Peter P. Lee, Marwan Fakih
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2018)